An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness

Phase 1/2 Completed 80 enrolled University of California, Los Angeles

Non-randomizedParallel-groupOpen-labelPrevention

Summary

Open label clinical trial of persons (adults) that will determine the safety and efficacy of the diet supplement oral mitoquinone/mitoquinol mesylate (Mito-MES) to prevent the development and progression of severe viral infections like COVID-19 after high-risk exposure to a person with possible respiratory viral infection such as SARS-CoV-2 infection in persons who will receive Mito-MES compared to persons who will not receive Mito-MES (controls).

Timeline

Start: 2022-04-28
Primary completion: 2023-05-09
Completion: 2023-05-09

Outcome

Met primary endpoint

paper 12 (30%) developed SARS-CoV-2 infection compared to 30 of the 40 controls (75%) PMID 38471990 ↗

Publications

Chen K, Jackson NJ, Kelesidis T. Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls. EBioMedicine. 2024 Apr;102:105042. doi: 10.1016/j.ebiom.2024.105042. Epub 2024 Mar 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MitoQ	Small molecule	20 mg	Oral